Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaldehyde | 2 | 2026 | 5 | 1.210 |
Why?
|
| Prostatic Neoplasms | 5 | 2026 | 304 | 0.870 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2026 | 178 | 0.830 |
Why?
|
| Electrocardiography | 2 | 2025 | 398 | 0.640 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 165 | 0.640 |
Why?
|
| Heart Failure | 4 | 2025 | 254 | 0.610 |
Why?
|
| Breath Tests | 3 | 2009 | 18 | 0.610 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 168 | 0.610 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 220 | 0.550 |
Why?
|
| Mouth Neoplasms | 2 | 2017 | 64 | 0.550 |
Why?
|
| Fanconi Anemia | 1 | 2017 | 3 | 0.510 |
Why?
|
| Androgen Antagonists | 3 | 2026 | 20 | 0.510 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2026 | 48 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 349 | 0.460 |
Why?
|
| Facial Injuries | 2 | 2012 | 5 | 0.440 |
Why?
|
| Lasers | 4 | 2026 | 68 | 0.400 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2025 | 9 | 0.380 |
Why?
|
| Protective Devices | 1 | 2012 | 5 | 0.360 |
Why?
|
| Heart-Assist Devices | 2 | 2025 | 38 | 0.360 |
Why?
|
| Spectrophotometry, Infrared | 3 | 2026 | 26 | 0.360 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 124 | 0.350 |
Why?
|
| Humans | 27 | 2026 | 29211 | 0.330 |
Why?
|
| Athletic Injuries | 1 | 2012 | 122 | 0.330 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 182 | 0.310 |
Why?
|
| Diagnosis, Oral | 2 | 2011 | 2 | 0.310 |
Why?
|
| Haptoglobins | 1 | 2009 | 22 | 0.300 |
Why?
|
| Cattle Diseases | 1 | 2009 | 18 | 0.300 |
Why?
|
| Respiratory Tract Infections | 1 | 2009 | 37 | 0.300 |
Why?
|
| Male | 17 | 2026 | 14126 | 0.290 |
Why?
|
| Aged | 10 | 2026 | 5648 | 0.290 |
Why?
|
| Mandibular Fractures | 1 | 2008 | 3 | 0.290 |
Why?
|
| Emergency Treatment | 1 | 2008 | 26 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2026 | 103 | 0.280 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2026 | 118 | 0.270 |
Why?
|
| Spectrophotometry | 1 | 2007 | 34 | 0.260 |
Why?
|
| Optics and Photonics | 1 | 2007 | 24 | 0.260 |
Why?
|
| Chemoradiotherapy | 2 | 2024 | 50 | 0.260 |
Why?
|
| Immunotherapy | 2 | 2026 | 171 | 0.250 |
Why?
|
| DNA Mismatch Repair | 1 | 2026 | 13 | 0.240 |
Why?
|
| CTLA-4 Antigen | 1 | 2026 | 11 | 0.240 |
Why?
|
| Fermentation | 1 | 2026 | 52 | 0.230 |
Why?
|
| Killer Cells, Natural | 1 | 2026 | 73 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 1 | 2026 | 80 | 0.230 |
Why?
|
| Pathology, Oral | 1 | 2005 | 1 | 0.220 |
Why?
|
| Oral Medicine | 1 | 2005 | 1 | 0.220 |
Why?
|
| Wearable Electronic Devices | 1 | 2025 | 16 | 0.220 |
Why?
|
| Heart Transplantation | 1 | 2025 | 43 | 0.220 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 6 | 0.220 |
Why?
|
| Ethanol | 1 | 2026 | 127 | 0.220 |
Why?
|
| Baroreflex | 1 | 2024 | 6 | 0.220 |
Why?
|
| Salvage Therapy | 1 | 2024 | 37 | 0.210 |
Why?
|
| Capecitabine | 1 | 2024 | 4 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2024 | 40 | 0.210 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 10 | 0.210 |
Why?
|
| Scrotum | 1 | 2024 | 9 | 0.210 |
Why?
|
| Machine Learning | 1 | 2025 | 98 | 0.210 |
Why?
|
| Middle Aged | 10 | 2026 | 7495 | 0.200 |
Why?
|
| Female | 12 | 2025 | 15825 | 0.200 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 205 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 79 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 221 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 103 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 434 | 0.180 |
Why?
|
| Brachytherapy | 1 | 2021 | 54 | 0.170 |
Why?
|
| Zygomatic Fractures | 1 | 2000 | 2 | 0.160 |
Why?
|
| Orbital Fractures | 1 | 2000 | 6 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2026 | 17 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2020 | 11 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 384 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 58 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 38 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 40 | 0.150 |
Why?
|
| Pulmonary Artery | 1 | 2019 | 69 | 0.150 |
Why?
|
| African Americans | 1 | 2021 | 353 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2020 | 271 | 0.140 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2021 | 70 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2025 | 1288 | 0.130 |
Why?
|
| Gases | 2 | 2007 | 23 | 0.120 |
Why?
|
| Adult | 6 | 2024 | 8130 | 0.120 |
Why?
|
| Prostatectomy | 2 | 2026 | 90 | 0.110 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2014 | 1 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 28 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 24 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2014 | 29 | 0.100 |
Why?
|
| Neoplasms | 1 | 2023 | 888 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 75 | 0.100 |
Why?
|
| Nitric Oxide | 2 | 2006 | 153 | 0.100 |
Why?
|
| Biomarkers | 2 | 2023 | 790 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 101 | 0.100 |
Why?
|
| Ireland | 1 | 2012 | 17 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 75 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 78 | 0.090 |
Why?
|
| Violence | 1 | 2012 | 31 | 0.090 |
Why?
|
| Remote Consultation | 1 | 2011 | 4 | 0.080 |
Why?
|
| Lacerations | 1 | 2011 | 8 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2011 | 77 | 0.080 |
Why?
|
| Young Adult | 4 | 2014 | 2877 | 0.080 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2011 | 65 | 0.080 |
Why?
|
| Wound Healing | 1 | 2011 | 127 | 0.080 |
Why?
|
| Absorption | 2 | 2007 | 14 | 0.080 |
Why?
|
| Beverages | 1 | 2009 | 24 | 0.070 |
Why?
|
| United Kingdom | 2 | 2011 | 80 | 0.070 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2009 | 23 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 33 | 0.070 |
Why?
|
| Oral Hemorrhage | 1 | 2008 | 1 | 0.070 |
Why?
|
| Water | 2 | 2007 | 135 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2026 | 2442 | 0.070 |
Why?
|
| Airway Obstruction | 1 | 2008 | 20 | 0.070 |
Why?
|
| Cattle | 1 | 2009 | 389 | 0.070 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 109 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2024 | 358 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 290 | 0.070 |
Why?
|
| Calibration | 1 | 2007 | 29 | 0.060 |
Why?
|
| United States | 2 | 2025 | 2270 | 0.060 |
Why?
|
| Time Factors | 2 | 2009 | 1619 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2009 | 274 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2026 | 3 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2026 | 11 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2007 | 135 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2026 | 1 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2026 | 2 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2026 | 32 | 0.060 |
Why?
|
| Prednisone | 1 | 2026 | 54 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2026 | 54 | 0.060 |
Why?
|
| Photoplethysmography | 1 | 2025 | 2 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 1020 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2024 | 2662 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 2070 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2026 | 153 | 0.060 |
Why?
|
| Mouth Diseases | 1 | 2005 | 6 | 0.060 |
Why?
|
| Education, Dental | 1 | 2005 | 10 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2026 | 303 | 0.060 |
Why?
|
| Emergency Medicine | 1 | 2005 | 16 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2025 | 114 | 0.050 |
Why?
|
| Colostomy | 1 | 2024 | 9 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 18 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2024 | 76 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2025 | 125 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2026 | 144 | 0.050 |
Why?
|
| Penis | 1 | 2024 | 17 | 0.050 |
Why?
|
| Education, Medical | 1 | 2005 | 71 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 250 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2026 | 301 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2023 | 45 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2005 | 249 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2023 | 61 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2023 | 74 | 0.050 |
Why?
|
| Adolescent | 3 | 2011 | 3255 | 0.050 |
Why?
|
| Phenotype | 1 | 2024 | 689 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2023 | 120 | 0.050 |
Why?
|
| Asthma | 1 | 2002 | 61 | 0.040 |
Why?
|
| Physics | 1 | 2021 | 2 | 0.040 |
Why?
|
| Hawaii | 1 | 2021 | 12 | 0.040 |
Why?
|
| Drug Industry | 1 | 2021 | 15 | 0.040 |
Why?
|
| Quality of Life | 1 | 2025 | 523 | 0.040 |
Why?
|
| Zygoma | 1 | 2000 | 3 | 0.040 |
Why?
|
| Proteins | 1 | 2023 | 256 | 0.040 |
Why?
|
| Orbit | 1 | 2000 | 12 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 158 | 0.040 |
Why?
|
| Radiography | 1 | 2000 | 203 | 0.040 |
Why?
|
| Child | 2 | 2011 | 2354 | 0.040 |
Why?
|
| Jugular Veins | 1 | 2019 | 13 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 244 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 526 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 218 | 0.040 |
Why?
|
| Animals | 1 | 2009 | 10806 | 0.030 |
Why?
|
| Nuclear Physics | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 12 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2014 | 20 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 111 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 328 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 484 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2011 | 10 | 0.020 |
Why?
|
| Sutures | 1 | 2011 | 15 | 0.020 |
Why?
|
| Photography | 1 | 2011 | 19 | 0.020 |
Why?
|
| Cicatrix | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Phone | 1 | 2011 | 20 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2011 | 46 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 96 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 233 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 129 | 0.020 |
Why?
|
| Students, Medical | 1 | 2011 | 102 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2009 | 26 | 0.020 |
Why?
|
| Caffeine | 1 | 2009 | 39 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2009 | 35 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 96 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 307 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 97 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 172 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2009 | 89 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 175 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 177 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 426 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 310 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 383 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1215 | 0.020 |
Why?
|
| Solutions | 1 | 2006 | 31 | 0.010 |
Why?
|
| Nitrogen Isotopes | 1 | 2006 | 19 | 0.010 |
Why?
|
| Solubility | 1 | 2006 | 73 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 94 | 0.010 |
Why?
|